REVERSE-IT: Bentracimab provides immediate, sustained reversal of ticagrelor effects

reverse it bentracimab provides immediate sustained reversal of ticagrelor effects

Sumary of REVERSE-IT: Bentracimab provides immediate, sustained reversal of ticagrelor effects:

  • November 15, 2021 3 min read Source/Disclosures Published by: Source: Bhatt DL, et al.
  • Presented at: American Heart Association Scientific Sessions;
  • Back to Healio An IV monoclonal antibody accomplished quick and sustained reversal of the antiplatelet effects of ticagrelor, according to the REVERSE-IT trial presented at the American Heart Association Scientific Sessions.
  • Bhatt The antiplatelet effects of ticagrelor (Brilinta, AstraZeneca), a P2Y12 inhibitor, cannot be reversed by platelet transfusion, so a reversal agent is an unmet need, Cardiology Today Intervention Section Editor Deepak L.
  • Bhatt, MD, MPH, executive director of interventional cardiology programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, told Healio.
  • “The way ticagrelor binds has allowed development of a monoclonal antibody called bentracimab (PhaseBio), which binds to ticagrelor or its active metabolite and is removed from the circulation.
  • “The benefits on platelet function kick in very quickly, by 5 to 10 minutes, and are sustained.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.